Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$5.81

0.265 (4.78%)

08:15
03/19/19
03/19
08:15
03/19/19
08:15

Diplomat Pharmacy price target lowered to $6 from $16 at Wells Fargo

Wells Fargo analyst Jamie Stockton lowered his price target for Diplomat Pharmacy to $6 from $16 following mixed December results and "disappointing" 2019 guidance. The analyst reiterates a Market Perform rating on the shares.

DPLO Diplomat Pharmacy
$5.81

0.265 (4.78%)

02/25/19
LEER
02/25/19
DOWNGRADE
LEER
Market Perform
Diplomat Pharmacy downgraded to Market Perform from Outperform at SVB Leerink
02/25/19
LEHM
02/25/19
NO CHANGE
Target $8
LEHM
Overweight
Diplomat infusion business alone may be worth current maket cap, says Barclays
Barclays analyst Steve Valiquette lowered his price target for Diplomat Pharmacy to $8 from $18 to reflect additional customer losses in the Pharmacy Benefits Management segment as well as new specialty pharmacy segment softness and less favorable drug mix. Diplomat could sell certain assets to raise cash to pay down debt if necessary, Valiquette tells investors in a research note. With the severe decline in the stock price on Friday, the enterprise value is now ~$1B, including debt of $600M, the analyst points out. He believes one could argue that Diplomat's specialty infusion business alone may be worth almost $1B given comp valuations, "so the PBM assets and remaining specialty pharmacy assets are essentially free at the current valuation." As such, Valiquette keeps an Overweight rating on the shares.
03/04/19
BARD
03/04/19
NO CHANGE
BARD
Baird investigation finds Ohio, like many buyers, paying too much for drugs
In a research note titled "Major Confusion: Does This Pass Your Sniff Test?," Baird analyst Eric Coldwell details the interplay between Cardinal Health's (CAH) generic marketing company Major Pharmaceuticals and CVS Health (CVS) in Ohio. In Major's catalog is Omeprazole, a generic version of Prilosec, which is available without a subscription. CVS Caremark, which had majority share of pharmacy benefit management services in Ohio, didn't use Maximum Allowable Cost for the product, which led to the state of Ohio paying $6.74 per tablet, or 19 times the amount somebody without a subscription can buy it, Coldwell tells investors in a research note, citing his own investigation. Meanwhile, over the course of five quarters in Ohio, Major's volume market share went from less than 2% to nearly 60% while dollar market share went from 12% to 95%, adds the analyst. He asks, "How does this happen?" The state of Ohio, "like so many other buyers, feels like it is paying too much for drugs," concludes Coldwell.
03/18/19
MZHO
03/18/19
NO CHANGE
Target $6
MZHO
Buy
Diplomat Pharmacy price target lowered to $6 from $8 at Mizuho
Mizuho analyst Ann Hynes on Friday lowered her price target for Diplomat Pharmacy to $6 from $8 following the company's Q4 results and reduced outlook. Diplomat emphasized 2019 will be a rebuilding year, due to challenging headwinds from pharmacy benefit management customer losses and volume pressure in the specialty business, Hynes tells investors in a research note. Further, the analyst thinks the increased commercial and Medicare Part D competitive pressures reduce earnings visibility post 2019. She keeps a Neutral rating on Diplomat Pharmacy.

TODAY'S FREE FLY STORIES

PPG

PPG

$118.89

0.665 (0.56%)

06:52
10/17/19
10/17
06:52
10/17/19
06:52
Earnings
PPG reports Q3 adjusted EPS $1.67, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
KeyCorp sees long-term ROTCE 16%-19% »

Long-term targets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AUMN

Golden Minerals

$0.22

0.0042 (1.91%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
Golden Minerals enters option agreement to sell Santa Maria Project »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLO

Allogene Therapeutics

$26.36

0.41 (1.58%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Conference/Events
Allogene Therapeutics management to meet with BTIG »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:51
10/17/19
10/17
06:51
10/17/19
06:51
Hot Stocks
KeyCorp sees Q4 net interest income 'relatively stable' »

In slides being presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

DOV

Dover

$95.71

-0.24 (-0.25%)

06:50
10/17/19
10/17
06:50
10/17/19
06:50
Earnings
Dover tightens FY19 adj. EPS view to $5.82-$5.85 from $5.75-$5.85 

Consensus $5.82.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

SON

Sonoco

$58.27

0.75 (1.30%)

06:49
10/17/19
10/17
06:49
10/17/19
06:49
Earnings
Sonoco narrows FY19 base EPS view to $3.50-$3.54 from $3.52-$3.62 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

DOV

Dover

$95.71

-0.24 (-0.25%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Dover reports Q3 adj. EPS $1.60, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 11

    Nov

ARQL

ArQule

$8.97

0.32 (3.70%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Initiation
ArQule initiated  »

ArQule initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:48
10/17/19
10/17
06:48
10/17/19
06:48
Earnings
Breaking Earnings news story on Sonoco »

Sonoco sees Q4 base EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SON

Sonoco

$58.27

0.75 (1.30%)

06:47
10/17/19
10/17
06:47
10/17/19
06:47
Earnings
Sonoco reports Q3 base EPS 97c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BWXT

BWX Technologies

$56.09

-0.33 (-0.58%)

06:46
10/17/19
10/17
06:46
10/17/19
06:46
Hot Stocks
BWX Technologies awarded $806M contract from U.S. Navy »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Recommendations
Netflix analyst commentary  »

SunTrust incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AAPL

Apple

$234.59

-0.67 (-0.28%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Periodicals
EU examining Apple Pay for antitrust concerns, FT reports »

Apple's Apple Pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

ALV

Autoliv

$80.64

0.93 (1.17%)

06:45
10/17/19
10/17
06:45
10/17/19
06:45
Upgrade
Autoliv rating change  »

Autoliv upgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$255.02

-19.58 (-7.13%)

06:44
10/17/19
10/17
06:44
10/17/19
06:44
Recommendations
ServiceNow analyst commentary  »

ServiceNow selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:43
10/17/19
10/17
06:43
10/17/19
06:43
Periodicals
We Company forms committee to consider financing lifeline, Reuters reports »

The We Company (WE) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$119.70

-0.25 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 14

    Jan

CDXC

ChromaDex

$3.41

0.41 (13.67%)

06:41
10/17/19
10/17
06:41
10/17/19
06:41
Hot Stocks
ChromaDex reports new study on nicotinamide riboside importance »

ChromaDex announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$55.47

0.46 (0.84%)

06:39
10/17/19
10/17
06:39
10/17/19
06:39
Downgrade
Brunswick rating change  »

Longbow downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MTB

M&T Bank

$159.14

0.27 (0.17%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Earnings
M&T Bank reports Q3 EPS $3.47, consensus $3.57 »

Reports Q3 common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NEPT

Neptune Wellness

$3.49

0.03 (0.87%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Neptune Wellness to provide extraction services to farming services operation »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSRGY

Nestle

$0.00

(0.00%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Nestle says portfolio management 'fully on track' »

Nestle notes that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNA

Snap-On

$157.68

-0.64 (-0.40%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Hot Stocks
Snap-On sees 2019 CapEx $95M-$105M »

Sees 2019 effective…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle backs underlying FY19 EPS in constant currency up vs. last year »

Full-year guidance for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle reports nine month sales CHF68.367B vs. CHF66.424B last year »

Organic growth reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.